In-Person Access Only | TBD CE/CME Credits
Please read: All programs remain free. Registrations will require a credit card as a cancellation hold. A fee of $50 will only be incurred in the event of a no-show or cancellation within 5 days without written confirmation to the Total Health Program Team. Industry representatives—defined as any individual who is employed by, contracted with, owns, or represents a drug, device, diagnostic, or other healthcare-related commercial entity, regardless of clinical credentials or licensure—are not permitted to attend Total Health events as general attendees. Members of industry must contact exhibits@totalhealthoncology.com
This symposium will provide a practical update on autologous hematopoietic stem cell transplantation (AHSCT) and CAR-T therapies for autoimmune rheumatologic, neurologic, and pulmonary diseases, highlighting emerging research and future innovation. The program will review clinical outcomes, evolving guidelines, and operational insights, including referral pathways, patient selection, and infrastructure needed to build and expand cell therapy programs. It will also showcase ongoing research and clinical trial trends while fostering multidisciplinary collaboration among clinicians, researchers, and program leaders in autoimmune cell therapy.
Conference Agenda
Saturday, September 26, 2026
7:30 AM
Coffee and Exhibits
8:00 AM
Program Chair Welcome
8:10 AM
Immune Reset as a Therapeutic Strategy: Where Specialties Align, and Where They Don’t
Examines how neurology, rheumatology, and transplant define success, failure, and acceptable risk differently despite shared immunologic mechanisms – setting a common interpretive framework
8:50 AM
Immune Reconstitution After AHSCT: What Changes Correlate with Clinical Benefit
Focuses on immune parameters that have correlated with durable outcomes, highlighting where biologic recovery does – and does not – translate into clinical control
9:10 AM
Patient Selection and Timing: Where Each Specialty Draws the Line
Compares specialty-specific thresholds for referral, contraindication, and risk tolerance and how these have decisions are informed by disease trajectory and available data
9:30 AM
Breakfast and Exhibits
9:45 AM
Non-CME Breakfast
10:30 AM
Systemic Sclerosis: When the Data Justify Taking Transplant-Level Risk
Reviews randomized and real-world AHSCT data in SSc, emphasizing survival, organ outcomes, and why this disease uniquely supports aggressive immune reset
11:10 AM
Interstitial Lung Disease as a Decision-Driver in Immune Reset
Explores how ILD trajectory influences treatment urgency, patient selection, and interpretation of response across autoimmune conditions
11:30 AM
Multiple Sclerosis: Where Immune Reset Fits – and Where It Doesn’t
Reframes immune-reset data in MS through the lens of disease stage, progression, and the limits imposed by irreversible neurologic injury
11:50 AM
Antibody-Mediated Neurologic Disease (MG, CIDP, SPS): Why These Disorders Challenge Conventional Therapy
Uses antibody-driven neurologic disease to illustrate why deep immune intervention may be necessary when traditional suppression fails
12:10 PM
Lunch and Exhibits
12:25 PM
Non-CME Lunch
1:00 PM
Housekeeping and Survey
1:10 PM
Depth vs. Durability of Response: What Long-Term Data Reveals About Disease Modification
Distinguishes transient suppression from sustained immune reprogramming using long-term outcomes from MS, ILD, and systemic sclerosis cohorts
1:30 PM
What Happens After “Success” Long-Term Monitoring and Late Effects
Addresses survivorship realities after immune reset, including infection risk, vaccination, secondary autoimmunity, and long-term follow-up models
1:50 PM
CD19 CAR-T in Autoimmune Disease: What the Early Clinical Signals Actually Show
Synthesizes published and ongoing trial data to assess depth of response, durability, safety, and how autoimmune CAR-T differs fundamentally from oncology experience (IIM, SLE, SSc, MS, MG, SPS)
2:30 PM
Breaks and Exhibits
2:45 PM
CAR-T Toxicity Outside Oncology: What is Similar, Different, or Unclear
Examines CRS, neurotoxicity, infection risk, and immune suppression in autoimmune populations, highlighting areas where oncology assumptions may not apply
3:05 PM
Beyond CD19: Targeting Plasma Cells and Autoantibody Production
Explores the rationale for plasma-cell-directed strategies and what antibody-mediated diseases suggest about future cellular targets
3:35 PM
Panel Discussion
4:35 PM
Networking Cocktail Hour
5:15 PM
Adjourn
Agenda Subject To Change. All times are MST.
-
Provide a current, practical update on AHSCT and CAR-T for autoimmune rheumatologic, neurologic, and pulmonary diseases
Share outcomes, guidelines, and operational experience
Clarify referral pathways, patient selection, and infrastructure needs
Showcase emerging research and clinical trial trends
Facilitate multidisciplinary collaboration and networking
-
-
Free registration for all healthcare providers
Expert sessions that present the most clinically relevant data, research, and clinical strategies
Real-time discussion and debate
Networking with peers, colleagues, and medical professionals
Access to the latest industry information and resources